Skip to main content
. Author manuscript; available in PMC: 2021 Jun 17.
Published in final edited form as: Biochemistry. 2021 May 19;60(21):1630–1641. doi: 10.1021/acs.biochem.1c00240

Figure 5.

Figure 5.

Clinical topoisomerase II poisons. The demethyl-epipodophyllotoxins (etoposide, etoposide phosphate, and teniposide), the anthracyclines (doxorubicin, daunorubicin, and idarubicin), and the anthracenedione mitoxantrone target topoisomerase II and are approved for clinical use in the United States. A scheme for the metabolism of etoposide by cytochrome P450 and oxidase is shown (top right).